A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Name: A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Published: 2016
License: Public Domain

Massachusetts General Hospital · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

malignant non-small cell neoplasm of lung stage iv, met exon 14 skipping, stage iv non-small cell lung cancer nsclc, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Related documents